Drug-Eluting Stent

Medtronic announced it received FDA approval for its next generation drug-eluting stent.

An ultrathin-strut bioresorbable polymer sirolimus-eluting stent continued to outperform a durable-polymer drug-eluting stent at 5 years, researchers reported at Cardiovascular Research Technologies.

According to a prespecified analysis of the BASKET-SMALL 2 trial, reperfusion with a drug-coated balloon in patients with CAD and small vessels may be noninferior to a drug-eluting stent, regardless of the indication for PCI.

DAPT for 1 months or 12 months in patients with ACS undergoing PCI with a cobalt-chromium everolimus-eluting stent (Xience family, Abbott Vascular).

Among patients receiving PCI with a drug-eluting stent, use of IVUS was associated with better CV outcomes, both within and beyond 1 year after the index procedure, according to new research.

A drug-eluting stent outperformed bare-metal stents for treatment of patients with lesions in the superficial femoral and proximal popliteal arteries, according to results of the EMINENT trial presented at VIVA 21.

Despite fewer bleeding events, 1-month dual antiplatelet therapy with clopidogrel failed to prove noninferiority vs. 12-month DAPT after PCI and stent implantation for ACS, according to a presenter.

Clopidogrel or aspirin monotherapy after 6 to 18 months of dual antiplatelet therapy following PCI.

In the SAFE-PAD cohort study of patients with peripheral artery disease designed in part by the FDA, there was no difference in mortality between those treated with paclitaxel-coated devices and those treated with uncoated devices.

In patients who underwent PCI with a drug-eluting stent and took dual antiplatelet therapy for 6 to 18 months, subsequent clopidogrel monotherapy was superior to aspirin monotherapy, according to data from the HOST-EXAM trial.